Telesta Receives FDA BLA Filing Notification Letter, Priority Review Designation for MCNA(1)

elesta Therapeutics Inc. (OTC:: BNHLF)  announced today that it has received its BLA Filing Notification for MCNA  from the U.S. Food and Drug Administration (FDA).  This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing.  In the same letter, the FDA communicated that it has designated the file for 6 month Priority Review and has set February 27, 2016 as the review goal date for MCNA. The FDA has also advised that it will be organizing an advisory committee to discuss the BLA application. Commenting on the FDA letter, Dr. Michael Berendt, Chief Executive Officer and Chief Scientist noted: "Today is a historic day for Telesta Therapeutics and for all of our staff and collaborators who have worked so diligently to advance our new treatment for non-muscle invasive bladder cancer towards potential regulatory approval early next year.  While we recognize that the FDA must complete its full review of our BLA filing before rendering its ultimate decision, we are working extremely hard, at all levels, to prepare for commercial launch in the United States."  About